Srikripa Devarakonda
Stock Analyst at Truist Financial
(4.94)
# 155
Out of 4,966 analysts
515
Total ratings
63%
Success rate
28.1%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COLL Collegium Pharmaceutical | Reiterated: Buy | $49 | $22.75 | +115.38% | 1 | Sep 9, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Buy | n/a | $21.27 | - | 5 | Sep 8, 2026 | |
| ABCL AbCellera Biologics | Reiterated: Buy | $30 | $10.89 | +175.48% | 14 | Sep 2, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $112 | $73.77 | +51.82% | 40 | Sep 1, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | n/a | $148.18 | - | 25 | Sep 1, 2026 | |
| CORT Corcept Therapeutics | Initiated Coverage: Buy | $164 | $112.79 | +45.40% | 1 | Aug 18, 2026 | |
| OABI OmniAb | Reiterated: Buy | n/a | $4.07 | - | 9 | Aug 18, 2026 | |
| SEPN Septerna | Reiterated: Buy | $43 → $59 | $38.51 | +53.21% | 7 | Aug 13, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,376 | $1,115.70 | +23.33% | 38 | Aug 11, 2026 | |
| ARVN Arvinas | Rated: Hold | $10 → $8.68 | $8.45 | +2.72% | 16 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 | $59.02 | +49.10% | 11 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $55.41 | - | 31 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 | $63.64 | +9.99% | 22 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $709 | $534.41 | +32.67% | 15 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.27 | - | 4 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $121.47 | - | 37 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.40 | - | 1 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $13 | $4.02 | +223.38% | 5 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $17 | $8.21 | +107.06% | 10 | Jul 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $136 | $116.47 | +16.77% | 23 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $44.40 | - | 34 | Jun 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $14.08 | - | 1 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.16 | - | 21 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.13 | - | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $377.35 | - | 15 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $139 → $214 | $129.41 | +65.37% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $25.61 | -10.17% | 15 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $812 | $781.49 | +3.90% | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $84 | $94.66 | -11.26% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.33 | n/a | 8 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $142 | $217.15 | n/a | 12 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.74 | n/a | 7 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $257.12 | n/a | 7 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $143.93 | n/a | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $27.72 | n/a | 10 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 15 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.32 | n/a | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $75.49 | n/a | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $7.32 | n/a | 13 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $38 | $0.000001 | n/a | 7 | Mar 20, 2023 |
Collegium Pharmaceutical
Sep 9, 2026
Reiterated: Buy
Price Target: $49
Current: $22.75
Upside: +115.38%
NewAmsterdam Pharma Company
Sep 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.27
Upside: -
AbCellera Biologics
Sep 2, 2026
Reiterated: Buy
Price Target: $30
Current: $10.89
Upside: +175.48%
Cytokinetics
Sep 1, 2026
Reiterated: Buy
Price Target: $112
Current: $73.77
Upside: +51.82%
Protagonist Therapeutics
Sep 1, 2026
Reiterated: Buy
Price Target: n/a
Current: $148.18
Upside: -
Corcept Therapeutics
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $164
Current: $112.79
Upside: +45.40%
OmniAb
Aug 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.07
Upside: -
Septerna
Aug 13, 2026
Reiterated: Buy
Price Target: $43 → $59
Current: $38.51
Upside: +53.21%
Eli Lilly and Company
Aug 11, 2026
Reiterated: Buy
Price Target: $1,376
Current: $1,115.70
Upside: +23.33%
Arvinas
Aug 10, 2026
Rated: Hold
Price Target: $10 → $8.68
Current: $8.45
Upside: +2.72%
Aug 10, 2026
Reiterated: Buy
Price Target: $88
Current: $59.02
Upside: +49.10%
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $55.41
Upside: -
Jul 31, 2026
Reiterated: Buy
Price Target: $70
Current: $63.64
Upside: +9.99%
Jul 31, 2026
Reiterated: Buy
Price Target: $709
Current: $534.41
Upside: +32.67%
Jul 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.27
Upside: -
Jul 29, 2026
Reiterated: Hold
Price Target: n/a
Current: $121.47
Upside: -
Jul 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.40
Upside: -
Jul 27, 2026
Reiterated: Buy
Price Target: $13
Current: $4.02
Upside: +223.38%
Jul 2, 2026
Reiterated: Buy
Price Target: $11 → $17
Current: $8.21
Upside: +107.06%
Jun 29, 2026
Rated: Buy
Price Target: $136
Current: $116.47
Upside: +16.77%
Jun 17, 2026
Reiterated: Buy
Price Target: n/a
Current: $44.40
Upside: -
Jun 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $14.08
Upside: -
May 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.16
Upside: -
Mar 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.13
Upside: -
Nov 5, 2025
Reiterated: Hold
Price Target: n/a
Current: $377.35
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $139 → $214
Current: $129.41
Upside: +65.37%
Oct 30, 2025
Reiterated: Buy
Price Target: $23
Current: $25.61
Upside: -10.17%
Oct 29, 2025
Reiterated: Buy
Price Target: $812
Current: $781.49
Upside: +3.90%
Oct 10, 2025
Reiterated: Buy
Price Target: $84
Current: $94.66
Upside: -11.26%
Aug 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.33
Upside: n/a
Jul 21, 2025
Downgraded: Hold
Price Target: $142
Current: $217.15
Upside: n/a
Jul 9, 2025
Rated: Hold
Price Target: n/a
Current: $1.74
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $257.12
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $143.93
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $27.72
Upside: n/a
Jan 28, 2025
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Dec 23, 2024
Rated: Hold
Price Target: n/a
Current: $1.32
Upside: n/a
Nov 12, 2024
Reiterated: Buy
Price Target: n/a
Current: $75.49
Upside: n/a
Oct 18, 2024
Rated: Buy
Price Target: $15
Current: $7.32
Upside: n/a
Mar 20, 2023
Downgraded: Hold
Price Target: $40 → $38
Current: $0.000001
Upside: n/a